Note: Descriptions are shown in the official language in which they were submitted.
CA 02231848 1998-03-12
W O 97/10239 PCT~DK96/00383
Acid Addition Salts of 2,3,4,5-tetrahydro-1H-3-benzazepine Compounds
The present invention relates to crystalline salts of tS) ( + )-8-chloro-5-
(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-
1 H-3-benzazepine-7-ol, their preparation and use as therapeutic agents.
International patent appl. No. W0 93/17012 discloses a class of com-
pounds exhibiting strong antidopaminergic effects and thus making them
useful in treatment of disorders in the central nervous system related to
dysfunctions of the dopamine D-1 receptor system, e.g. psychosis, pain,
15 depression and Parkinson's disease.
In example 3 of International appl. No. W0 93/17012 the preparation of
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yi)-3-methyl-
2,3,4,5-tetrahydro-lH-3-benzazepine-7-ol of formula l:
C 1~ ~N--CH ( I )
c
is described.
Because of its poor solubility, it is preferred that the compound of
formula I is used as a therapeutic agent in the form of an acid addition
salt.
CA 02231848 1998-03-12
W O 97/10239 PCTADK96/00383
- 2 -
Further, it has been found that some acid addition salts of the compound
of formula I do form alternate polymorphic forms. This is pharmaceuti-
cally undesirable because of the potential that the salt occurs in more
than one crystalline form making it very difficult to predict how the
5 various parts of the body will react to the different crystalline forms.
In general, for commercial use it is important to have a physiologically
acceptable salt with good bioavailability, good handling properties, and
reproducible crystalline form.
Surprisingly, it has now been found that a series of new pharmaceuti-
cally acceptable acid addition salts of the compound of formula I can be
obtained in a reproducible crystalline form.
15 Accordingly, the present invention provides a series of crystalline salts of
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol derived from organic acids
such as fumaric, tartaric, maleic and mandelic acids.
Preferred salts of the invention are (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-
dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7-
ol, hemifumarate; (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofu-
ran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol, L( + )-hemi-
tartrate; (S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-
methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol, maleate; (S) (+)-8-
chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-
tetrahydro-1 H-3-benzazepin-7-ol, L( + )-mandelate.
The acid addition salts of the (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihy-
drobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol
are prepared by dissolving the acid of the corresponding addition salt and
CA 02231848 1998-03-12
W O 97/10239 PCTADK96/00383
- 3 -
the compound of formula I in a common solvent, and crystallizing the
resulting salt from the solution.
Examples of the common solvents include lower aliphalic alcohols such
as ethanol, methanol, 2-propanol, 2-butanol, 1-hexanol and solvents like
isobutylmethylketone and tetrahydrofuran.
The present invention also provides pharmaceutical compositions com-
prising crystalline salts of (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydro-
benzofuran-7-yl)-3-methyl-2,3,4,~-tetrahydro-1 H-3-benzazepine-7-ol and
a pharmaceutically acceptable carrier.
The compositions of this invention are usually adapted for oral admini-
stration, but formulations for dissolution for parenteral administration are
also within the scope of this invention.
The composition is usually presented as a unit dose composition contain-
ing 0.01 mg - 1000 mg for oral dosing. Typical dosage for antiphsy-
chotic effect would vary between 0.1 - 400 mg, preferably between
1.0 - 200 mg per day divided in 2 or 3 doses when administered orally.
Preferred unit dosage forms include in solid form, tablets or capsules, in
liquid form, solutions, suspensions, emulsions, elixirs or capsules filled
with the same, or in form of sterile injectable solutions.
The composition of this invention may be formulated by conventional
methods of galenic pharmacy.
Conventional excipients are such pharmaceutically acceptable organic or
30 inorganic carrier substances suitable for parenteral or oral application
which do not deleteriously react with the active compound.
CA 02231848 1998-03-12
W O 97/10239 PCTADK96/00383
Examples of such carriers are water, salt solutions, alcohols,
polyethylene glycols, polyhydroxyethoxylated castor oil, syrup, peanut
oil, olive oil, gelatin, lactose, terra alba, sucrose, agar, pectin, acacia,
amylose, magnesium stearate, talc, silicic acid, stearic acid, fatty acid
5 monoglycerides and diglycerides, pentaerythritol fatty acid esters,
hydroxymethylcellulose and polyvinylpyrrolidone.
The pharmaceutical preparations can be sterilized and mixed, if desired,
with auxiliary agents, such as binders, lubricants, preservatives, dis-
10 integrants, stabilizers, wetting agents, emulsifiers, salt for influencingosmotic pressure, buffers and/or colouring substances and the like,
which do not deleteriously react with the active compound.
For parenteral application, particularly suitable are injectable solutions or
15 suspensions, preferably aqueous solutions with the active compound
dissolved in polyhydroxylated castor oil.
For oral administration, particularly suitable are tablets, dragees, or cap-
sules having talc and/or a carbohydrate carrier or binder or the like, the
20 carrier preferably being lactose and/or corn starch and/or potato starch.
A syrup, elixir or like can be used when a sweetened vehicle can be
employed .
A typical tablet, which may be prepared by conventional tabletting tech-
25 niques, contains:
Active compound 10 mg !'
Lactosum 67.8 mg Ph.Eur.
Avicel~' 31.4 mg
AmberliteC' IRP 88 1.0 mg
Magnesii stearas 0.25 mg Ph.Eur.
CA 02231848 1998-03-12
W O 97/10239 PCT~DK~6/0~3
- 5 -
The invention also provides methods of treatment of certain disorders in
the central nerveous system related to dysfunctions of the dopamine D-1
receptor system, e.g. psychosis, depression, pain and Parkinson's
disease in mammals including humans which methods comprises admini-
5 stering an effective amount of a pharmaceutically acceptable crystallinesalt of (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-
methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol.
The invention further provides pharmaceutically acceptable crystalline
salts of (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-
methyl-2,3,4,5-tetrahydro-1 H-3-benzazepine-7-ol for use in the treatment
of disorders in the central nerveous system related to dysfunctions of the
dopamine D-1 receptor system, e.g. psychosis, depression, pain and
Parkinson's disease.
The acid addition salts of (S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydro-
benzofuran-7-yl)-3-methyl-2,3,4,5-~etrahydro-1 H-3-benzazepine-7-ol of
the invention were synthesized and crystallized from common solvents
as described in the following examples.
EXAMPLE 1
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol, hemifumarate
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol (7.97 9, 20 mmol) was dis-
solved 99% ethanol at 70~C. Fumaric acid (2.32 g, 20 mmol) was
30 added. The solution was cooled to 0~C, and the resulting suspension
was filtered. The filtercake was washed with 99% ethanol (3 x 20 ml)
and dried to constant weight.
-
CA 02231848 1998-03-12
W O 97/10239 PCT~DK96/00383
- 6 -
Yield: 8.80 9 (96%) of white crystalline product. M.p. by DSC: 298~C.
Elemental Analysis: (C21H20CI3N,04, 456.8 g/mol)
Calculated: C 55.22 H 4.41 N 3.07 %
Found: C 55.30 H 4.55 N 3.94 %
Alternate polymorphic forms: None
EXAMPLE 2
(S) (+)-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol, L~ + )-hemitartrate
The preparation was carried out analogously to the preparation in
Example 1 using L( + )-tartaric acid and 20 mmol of the compound of for-
mula 1.
Yield: 7.75 g (82%) of white crystalline product. M.p. by DSC: 276~C.
Elemental Analysis: (C2lH2lCI3NlO5, 473.8 g/mol~:
Calculated: C 53.24 H 4.47 N 2.96 ~/O
Found: C 53.21 H 4.55 N 2.80 ~/0
Alternate polymorphic form: None
EXAMPLE 3
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro- 1 H-3-benzazepin-7-ol, maleate
The preparation of the compound was carried out analogously to the
preparation in Example 1 using maleic acid, and 20 mmol of the com-
pound of formula 1.
CA 02231848 1998-03-12
W O 97/10239 PCTADK96/00383
- 7 -
Yield: 7.61 9 ~74%) of white crystalline product. M.p. by DSC: 234OC,
Elemental Analysis: (C23H22CI3Nl08, 514.8 g/mol):
Calculated: C 53.66 H 4.31 N 2.72 %
Found: C 53.79 H 4.37 N 2.56 %
Alternate polymorphic form: None
EXAMPLE 4
(S) ( + )-8-chloro-5-(5,6-dichloro-2,3-dihydrobenzofuran-7-yl)-3-methyl-
2,3,4,5-tetrahydro-1 H-3-benzazepin-7-ol, L( ~ )-mandelate
The preparation of the compound was carried out analogously to the
preparation in Example 1 using L( +)-mandelic acid, and 20 mmol of the
compound of formula 1.
Yield: 10.35 9 (94%) of white crystalline product. M.p. by DSC: 249~C.
Elemental analysis: (C27H2~CI3N105, 550.9 g/mol):
Calculated: C 58.87 H 4.76 N 2.54 %
Found: C 58.97 H 4.88 N 2.50 %
Alternate polymorphic form: None
